JPMorgan analyst Richard Vosser lowered the firm’s price target on Novo Nordisk (NVO) to DKK 350 from DKK 500 and keeps an Overweight rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk downgraded to Hold from Buy at Argus
- Novo Nordisk cut to Hold at Argus on falling share of Wegovy/Ozempic
- LLY, PFE: Eli Lilly’s Mounjaro, Pfizer’s Cancer Drug Added to China’s State Insurance List
- Mixed options sentiment in Novo Nordisk with shares up 0.39%
- Eli Lilly Stock (LLY) Gets Multiple Price Target Increases as Rally Continues